A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
- Conditions
- HIV Infections
- Registration Number
- NCT00004581
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of this study is to compare the safety and effectiveness of 2 anti-HIV drug combinations in HIV-infected patients. Both combinations will include nevirapine (NVP), 2 nucleoside reverse transcriptase inhibitors (NRTIs), and at least 1 protease inhibitor (PI). One combination will include a new protease inhibitor, ABT-378, combined in a capsule with ritonavir (RTV).
- Detailed Description
Patients receive 1 of the following:
1. ABT-378/RTV plus NVP plus 2 NRTIs; or
2. Investigator-selected PI(s) plus NVP plus 2 NRTIs.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (88)
Univ of Alabama at Birmingham
🇺🇸Birmingham, Alabama, United States
Phoenix Body Positive
🇺🇸Phoenix, Arizona, United States
Pacific Oaks Med Group
🇺🇸Beverly Hills, California, United States
Orange County Ctr for Special Immunology
🇺🇸Fountain Valley, California, United States
AIDS Healthcare Foundation
🇺🇸Los Angeles, California, United States
Tower ID Med Associates
🇺🇸Los Angeles, California, United States
UCLA CARE Ctr
🇺🇸Los Angeles, California, United States
San Francisco Veterans Administration Med Ctr
🇺🇸San Francisco, California, United States
Harbor - UCLA Med Ctr
🇺🇸Torrance, California, United States
Yale Univ / AIDS Clinical Trials Unit
🇺🇸New Haven, Connecticut, United States
Scroll for more (78 remaining)Univ of Alabama at Birmingham🇺🇸Birmingham, Alabama, United States